Siler PanowskiDirector of Biology, Solid Tumors at Allogene, USA
Dr. Siler Panowski is a director of biology and the head of the solid tumor department at Allogene Therapeutics. He is directly involved in all aspects of the solid tumor portfolio, including strategy, preclinical development, and IND filings, and is the research lead for Allogene’s clinical candidate, ALLO-316. Additionally, Dr. Panowski’s group focuses on modifications to overcome the solid tumor microenvironment, including discovery and development of Allogene’s TurboCAR technology. Dr. Panowski has over twelve years of industry experience targeting solid tumors, including work on ADCs, CD3 bispecifics, and CAR T at Pfizer and Genentech.